We’re a company that takes on the toughest health challenges. But we do more than treat diseases—we aim to make a remarkable impact on people’s lives. We are AbbVie, a highly focused research-driven biopharmaceutical company.
- 1 What We Do
- 2 History
- 3 Controversies
- 4 Top 5 Recent Tweets
- 5 Top 5 Recent News Headlines
- 6 Top 5 Lifetime Tweets
- 7 Top 5 Lifetime News Headlines
What We Do
Our ~30,000 employees are scientists, researchers, communicators, manufacturing specialists and regulatory experts located around the globe. We come up with new approaches to addressing today’s health issues—from life-threatening illness to chronic conditions.
We target specific difficult-to-cure diseases where we can leverage our core R&D expertise to advance science. We’re constantly working to create solutions that go beyond treating the illness to have a positive impact on patients’ lives, on societies—and on science itself.
At AbbVie, we see a future full of possibility, where health is in reach and patient lives are improved. See our employees, our science and our hope for tomorrow:
Patients: Making an impact on more lives
To understand the patient journey, we collaborate with peers, academics, clinical experts, front-line practitioners, governments and advocacy groups. This fuels us to develop and deliver new solutions that truly make a difference.
Science: Finding better solutions to the world's toughest challenges
Research and innovation are the cornerstones of our business. We advance leading-edge science through a dynamic and collaborative approach. This enables us to find better solutions for treating the world’s most challenging diseases. We focus on discovering, developing and delivering drugs in therapeutic areas where we have proven expertise—and can make an impact. This includes:
- General Medicine
Partnerships: Working together to make a difference
Our partners share our commitment to solving the world’s greatest health needs. That’s why we collaborate with peers, universities, clinical experts, governments and advocacy groups to seek new solutions for patients throughout the world. By working together, we combine the best efforts, thinking and resources to find better solutions for patients.
Responsibility: Passionate about our work, responsible in our actions
At AbbVie, it’s both what we do and how we do it that matter. We go beyond medicine, using our resources to improve health care and communities. We’re committed to:
- Improving health outcomes. We’re targeting unmet needs and working to enhance access to health care across geographies.
- Operating responsibly. It’s the very basis of how AbbVie does business. We are committed to cultivating an ethical, transparent and inclusive culture to drive sustainable growth.
- Contributing to communities. We’re passionate about partnering with our communities to address challenges of the underserved.
Culture: Fostering innovation and discovery
We are a diverse, inclusive organization with people who reflect the thousands of communities we serve around the world. For all of us, working at AbbVie is more than a job. It’s a purpose that leads to better lives for other people, across the world. When the stakes are as high as a patient’s well-being, the best ideas must rise to the top, no matter where they begin.
|Type||Public / Private|
|Headquarters||Lake Bluff, Illinois, United States|
|Key people|| Richard A. Gonzalez
(Chairman & CEO)
|Number of employees||30000|
AbbVie may have been founded in 2013, but our roots run deep. In 2013, we became a separate company from Abbott, though we share a common legacy and strong prospects for future success.
Our name represents our connection to the past and the future. When we became our own company, AbbVie formed a new kind of enterprise—a biopharmaceutical company. We blend the stability, global scale, resources and commercial capabilities of a pharmaceutical company with the focus and culture of a biotech.
Today, our ~30,000 employees around the world focus on delivering transformational medicines and therapies that offer significant patient benefits.
Major concern regarding AbbVie by the U.S. Food and Drug Administration is due to the deaths linked back to its North Chicago manufacturing facility. The FDA was concerned that AbbVie did not take any initiative to look into five deaths that were tied to lots from a manufacturing facility in North Chicago. Upon further investigation, the FDA found that there were another 8 to 11 complaints that had been unaccounted for. The agency indicated the way AbbVie dealt with the death threats was “inadequate.” The FDA noted other inadequacies such as AbbVie’s lack of evaluating reserve samples for evidence of deterioration. Furthermore, AbbVie has made controversy due to Humira’s major price increase over the last few years. According to the International Federation of Health Plans, Humira is available in countries outside the United States for a fraction of the price.
Top 5 Recent Tweets
|August 19, 2019||ScottGottliebMD||To put this in perspective, Merck ANNUAL net income for 2018 was (roughly) $6.22B, AbbVie was $5.687B, Bristol-Myer… https://t.co/q8qL2ctr0K|
|August 17, 2019||Reuters||AbbVie prices new rheumatoid arthritis drug at $59,000 a year https://t.co/otvrmYWeDM https://t.co/y7B0z3wcDe|
|August 16, 2019||Reuters||AbbVie prices new rheumatoid arthritis drug at $59,000 a year https://t.co/7N7r8t0rAW https://t.co/FaPc05Ra82|
|August 22, 2019||JohnCendpts||4 years ago AbbVie paid $350M; you could buy 3 now for that and have enough change left over to buy a PD-1. https://t.co/AJlZ3EO4lc|